Functional Fluidics’ biomarkers are unique diagnostic platforms that assess the health of red blood cells.

 

Red Blood Cell Biomarkers

Functional Fluidics proprietary testing platforms assess key properties underpinning red blood cell function and survival.

Our biomarkers assess the health of red blood cells by replicating the environment that they experience in our bodies and providing that information to doctors and scientists allowing them to make better decisions about drug development and patient care.

Solutions for Clinical Providers, Academic, Pharma & BioTech Partners

Our proprietary biomarkers support drug validation and patient monitoring:

  • Clinical Providers on the front lines caring for patients who need clinical tools to help monitor care.
  • Pharmaceutical & Biotech companies developing therapies that affect the health of red blood cells
  • Academics studying subjects and measurement of blood function through baseline and crisis events.
img02-1
 
03-3
 

Flow Adhesion Assay

Cell adhesion is a complex mechanism involved in a variety of processes including cell migration and invasion, wound healing, tissue remodeling, and micro-vascular occlusion.

  • Our Flow Adhesion Assays capture the adhesive properties of an individual’s blood cells during conditions that simulate physiologic blood flow.

LEARN MORE

1180807912411244.RoClR4ZMZHqCZURnNzpL_height640

Mechanical Fragility Assay

Our Mechanical Fragility Assay determines the stability of the intact red blood cell membrane, which indicates the health and ability to survive extremal stress which may predict survival.

Learn More

002
 

Our Services

Functional Fluidics is a CLIA certified lab that offers the following services.

  • new01-2
    Send Out Testing Services

    Health care providers use our tests to aid in patient monitoring as a clinical support tool

    LEARN MORE
  • 001-2
    Contract Research Services:

    Our biomarkers are used by our pharma and biotech partners to help quantify the effects of drug therapies on blood function over time.

    LEARN MORE
003-2
 
 

Why Choose Functional Fluidics?

  • New Project

    Proprietary Lab Tests

  • New Project(1)

    CLIA Certified Lab

  • New Project(5)

    Complex Tests Experience

  • New Project(2)

    Thought Leader Access

  • New Project(3)

    Specialized Staff

  • New Project(4)

    Strong Industry Relationships

Functional Fluidics Assays

Our suite of proprietary cell function assays can help validate assumptions or support clinical claims.

  • 10
    Flow Adhesion of whole blood on VCAM-1 (FA-WB-VCAM)
    LEARN MORE
  • 11
    Flow Adhesion of whole blood on P-Selectin (FA-WB-Psel)
    LEARN MORE
  • 12
    Mechanical Fragility – Normoxia (MF)
    LEARN MORE
 

Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS)

04-1
 

Sickle cell disease (SCD) is characterized by frequent and unpredictable vaso-occlusive episodes (VOEs) that produce severe pain, organ damage, and early death. Lack of reliable biomarkers to objectively define VOEs, hinders the development of clinically useful interventions to improve the care for these patients.

Functional Fluidics recently participated in a ground-breaking study involving sickle cell patients. This non-interventional, longitudinal, 6-month study aimed to develop tools to identify VOCs in SCD patients with or without health care utilization.

The study data suggest that Functional Fluidics FA-WB-VCAM assay may serve as a predictive biomarker for impending VEEs, and a monitoring biomarker to assess response to SCD-modifying therapies.

LEARN MORE
04-1

Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by Electronic Patient-Reported Outcomes, Actigraphy, and Biomarkers

Functional Fluidics Biomarker Assay Featured in ELIPSIS article in American Society of Hematology (ASH) Blood Magazine

Key Points

  • Feasibility of monitored out-of-hospital pain and patient-reported VOC days as endpoints for clinical trials in SCD is demonstrated.
  • ePROs, actigraphy, and laboratory biomarkers enable improved identification and assessment of in-hospital and out-of-hospital VOCs.
LEARN MORE
blood
 

Publications & Abstracts

Hemolytic Biomarkers Predict Adhesiveness of Sickle Blood Cells in a Clinical Adhesion Bioassay

The objective of this study was to identify hematologic lab values that contribute to cellular adhesion in our clinical adhesion bioassay.

Evaluation of Coagulation and Inflammatory Markers in Pediatric Patients on Extracorporeal Membrane Oxygenation (ECMO)

The aims of this study were to evaluate if novel laboratory tests could better predict patients at risk for bleeding and/or thrombosis compared to routine laboratory tests

Longitudinal Evaluation of a Standardized P-Selectin Flow Adhesion Bioassay: Potential Role for the Assessment and Prediction of Vaso-Occlusive Episodes in Sickle Cell Disease

Sevuparin blocks sickle blood cell adhesion and sickle-leucocyte rolling on immobilized L-selectin in a dosedependent manner

Impact of environment on Red Blood Cell ability to withstand mechanical stress

An approach to measuring RBC haemolysis and profiling RBC mechanical fragility

Low molecular weight heparin inhibits sickle erythrocyte adhesion to VCAM-1 through VLA-4 blockade in a standardized microfluidic flow adhesion assay

A Longitudinal Study to Identify and Assess Adhesion Indices during Vaso-Occlusive Crises in Adults and Adolescents with Sickle Cell Disease